Drugs / MK-1403
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07677163 | Jul → Sep 2026 overdue | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07242469 | Dec 2025 → Aug 2026 overdue | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07242469 ↗ |
| Route | Oral | “MK-1403 administered orally.” NCT07242469 ↗ |